Siddique A. Abbasi, MD, was an Assistant Professor of Medicine at the Warren Alpert Medical School of Brown University, a staff cardiologist at Rhode Island Hospital, and a staff cardiologist and Director of Heart Failure, Echocardiography, and Cardiac Magnetic Resonance at the Providence VA Medical Center. He was the Principal Investigator of a 5-month pilot project form the CPVB COBRE entitled, “Pulmonary Artery Stiffness and Right Ventricular Fibrosis in Pulmonary Hypertension: A Magnetic Resonance Study.” Dr. Abbasi’s project investigated the relationship between pulmonary artery stiffness to right ventricular fibrosis in an effort to better understand the maladaptive right ventricular response to increased ventricular pressure in pulmonary hypertension (Jankowich M, Abbasi SA, et al. Am J Respir Crit Care Med. 2019 May 30).

Dr. Abbasi completed a combined BA/MD program at St. Louis University where he studied Philosophy. He completed his residency in Internal Medicine at the University of Washington in Seattle, followed by a clinical cardiology fellowship at the University of Illinois. Dr. Abbasi then completed a post-doctoral fellowship in Cardiac MRI at the Brigham and Women’s Hospital/Harvard Medical School. He stayed on at the Brigham and Women’s Hospital for a T32 research fellowship in Advanced Cardiovascular Imaging, while earning his Masters in Science (Epidemiology) at the Harvard T.H. Chan School of Public Health.

Dr. Abbasi’s primary research interest is in the study of cardiometabolic diseases with a focus on therapeutic interventions for heart failure. Dr. Abbasi is currently a Medical Director and Global Development Lead for Heart Failure at Amgen, where he oversees the clinical development of omecamtiv mecarbil, a first-in-class direct myosin activator for the treatment of heart failure. H specific responsibilities include execution of the pivotal Phase 3 cardiovascular outcomes study in heart failure, GALACTIC-HF, developing global product strategy as a member of the Product Team, leading development strategy and evidence generation activities in observational, non-clinical, and clinical research teams, and communicating project strategy to governance bodies. In addition, he continues to study metabolic diseases as a part of Amgen’s early development team studying therapeutic targets for obesity.